Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation.

Rees L, Tizard EJ, Morgan AJ, Cubitt WD, Finerty S, Oyewole-Eletu TA, Owen K, Royed C, Stevens SJ, Shroff RC, Tanday MK, Wilson AD, Middeldorp JM, Amlot PL, Steven NM.

Transplantation. 2009 Oct 27;88(8):1025-9. doi: 10.1097/TP.0b013e3181b9d918.

PMID:
19855249
2.

Rapamycin-induced remission of Kaposi's sarcoma is not associated with expansion of cytotoxic T-lymphocyte subsets.

Walsh SB, Summers SA, Amlot PL, Sheaff MT, Neild GH.

NDT Plus. 2008 Oct;1(5):313-5. doi: 10.1093/ndtplus/sfn068. Epub 2008 Jun 16.

4.

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, Amlot PL, Kelly D, MacGilchrist A, Gandhi MK, Swerdlow AJ, Crawford DH.

Blood. 2007 Aug 15;110(4):1123-31. Epub 2007 Apr 27.

PMID:
17468341
5.

Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases.

Wilkie GM, Taylor C, Jones MM, Burns DM, Turner M, Kilpatrick D, Amlot PL, Crawford DH, Haque T.

J Immunother. 2004 Jul-Aug;27(4):309-16.

PMID:
15235392
6.

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.

Haque T, Wilkie GM, Taylor C, Amlot PL, Murad P, Iley A, Dombagoda D, Britton KM, Swerdlow AJ, Crawford DH.

Lancet. 2002 Aug 10;360(9331):436-42.

PMID:
12241714
7.

Peripheral lymphocyte subsets in the management of PTLD.

Gupte GL, Beath SV, Amlot PL, James C, Kelly DA, McKiernan PJ, DeVille De Goyet J.

Transplant Proc. 2002 Aug;34(5):1782-3. No abstract available.

PMID:
12176574
8.

A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin.

Gordon FH, Hamilton MI, Donoghue S, Greenlees C, Palmer T, Rowley-Jones D, Dhillon AP, Amlot PL, Pounder RE.

Aliment Pharmacol Ther. 2002 Apr;16(4):699-705.

9.

Restoring cellular differentiatin in posttransplant lymphoproliferative disease.

Amlot PL.

Transplantation. 2002 Jan 27;73(2):163-5. No abstract available.

PMID:
11821723
10.

Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells.

Haque T, Taylor C, Wilkie GM, Murad P, Amlot PL, Beath S, McKiernan PJ, Crawford DH.

Transplantation. 2001 Oct 27;72(8):1399-402.

PMID:
11685111
11.

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE.

Gastroenterology. 2001 Aug;121(2):268-74.

PMID:
11487536
13.

Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms.

Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, Brown D, Amlot PL, Williams R, Vergani D, Dusheiko GM, Bertoletti A.

Hepatology. 2000 Nov;32(5):1117-24.

PMID:
11050064
14.

Follicular dendritic cells share a membrane-bound protein with fibroblasts.

Bofill M, Akbar AN, Amlot PL.

J Pathol. 2000 Jun;191(2):217-26.

PMID:
10861584
15.

Disappearance of an Epstein-Barr virus-positive post-transplant plasmacytoma with reduction of immunosuppression.

Rees L, Thomas A, Amlot PL.

Lancet. 1998 Sep 5;352(9130):789. No abstract available.

PMID:
9737292
16.

Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients.

Haque T, Amlot PL, Helling N, Thomas JA, Sweny P, Rolles K, Burroughs AK, Prentice HG, Crawford DH.

J Immunol. 1998 Jun 15;160(12):6204-9.

17.

Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.

Vorechovsk√Ĺ I, Luo L, Dyer MJ, Catovsky D, Amlot PL, Yaxley JC, Foroni L, Hammarstr√∂m L, Webster AD, Yuille MA.

Nat Genet. 1997 Sep;17(1):96-9.

PMID:
9288106
20.

Prolonged immunosuppressive effect and minimal immunogenicity from chimeric (CD25) monoclonal antibody SDZ CHI 621 in renal transplantation.

Kovarik JM, Rawlings E, Sweny P, Fernando O, Moore R, Griffin PJ, Fauchald P, Albrechtsen D, Sodal G, Nordal K, Amlot PL.

Transplant Proc. 1996 Apr;28(2):913-4. No abstract available.

PMID:
8623459
21.

Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipients.

Kovarik JM, Rawlings E, Sweny P, Fernando O, Moore R, Griffin PJ, Fauchald P, Albrechtsen D, Sodal G, Nordal K, Amlot PL.

Transpl Int. 1996;9 Suppl 1:S32-3.

PMID:
8959785
22.

Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation.

Amlot PL, Rawlings E, Fernando ON, Griffin PJ, Heinrich G, Schreier MH, Castaigne JP, Moore R, Sweny P.

Transplantation. 1995 Oct 15;60(7):748-56.

PMID:
7570988
23.

A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.

Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V, et al.

Blood. 1993 Nov 1;82(9):2624-33.

PMID:
8219217
24.

Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.

Lazarovits AI, Rochon J, Banks L, Hollomby DJ, Muirhead N, Jevnikar AM, White MJ, Amlot PL, Beauregard-Zollinger L, Stiller CR.

J Immunol. 1993 Jun 1;150(11):5163-74.

PMID:
7684422
25.

Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection.

Lazarovits AI, Rochon J, Banks L, Hollomby DJ, Muirhead N, Jevnikar AM, White MJ, Amlot PL, Beauregard-Zollinger L, Stiller CR.

Transplant Proc. 1993 Feb;25(1 Pt 1):820-2. No abstract available.

PMID:
7679844
26.

Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody.

Kirkham BW, Pitzalis C, Kingsley GH, Chikanza IC, Sabharwal S, Barbatis C, Grahame R, Gibson T, Amlot PL, Panayi GS.

Br J Rheumatol. 1991 Dec;30(6):459-63.

PMID:
1720991
27.

The effect of a chimeric mouse-human CD7 antibody on human T, natural killer, and lymphokine-activated killer cell activity in vitro.

Akbar AN, Amlot PL, Hawkins C, Newsholme W, Delaney S, Borthwick N, Janossy G.

Transplantation. 1991 Aug;52(2):325-30.

PMID:
1714642
28.

Inhibition of alloresponsive naive and memory T cells by CD7 and CD25 antibodies and by cyclosporine.

Akbar AN, Amlot PL, Ivory K, Timms A, Janossy G.

Transplantation. 1990 Nov;50(5):823-9.

PMID:
1700506
29.

The development of primed/memory CD8+ lymphocytes in vitro and in rejecting kidneys after transplantation.

Akbar AN, Amlot PL, Timms A, Lombardi G, Lechler R, Janossy G.

Clin Exp Immunol. 1990 Aug;81(2):225-31.

30.

Antibodies of different human IgG subclasses show distinct patterns of affinity maturation after immunization with keyhole limpet haemocyanin.

Devey ME, Bleasdale-Barr KM, Bird P, Amlot PL.

Immunology. 1990 Jun;70(2):168-74. Erratum in: Immunology 1990 Sep;71(1):152.

32.

Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions.

Heinrich G, Gram H, Kocher HP, Schreier MH, Ryffel B, Akbar A, Amlot PL, Janossy G.

J Immunol. 1989 Dec 1;143(11):3589-97.

PMID:
2479683
33.

Lack of specialized antigen-presenting cells (IDCs) in donor heart, kidney, liver, and lung at transplantation.

Amlot PL, Taylor P, Rose M, Sweny P, Janossy G, Yacoub M.

Transplant Proc. 1989 Feb;21(1 Pt 1):169-70. No abstract available.

PMID:
2495600
34.

The expression of T cell receptor-associated proteins during T cell ontogeny in man.

Campana D, Janossy G, Coustan-Smith E, Amlot PL, Tian WT, Ip S, Wong L.

J Immunol. 1989 Jan 1;142(1):57-66.

PMID:
2783327
35.

Neoepitopes expressed by immune complexes.

Amlot PL.

Complement Inflamm. 1989;6(3):236-48. Review.

PMID:
2472925
36.

Leukaemia and lymphoma treatment with autologous bone marrow transplantation: preclinical studies.

Janossy G, Campana D, Amlot PL.

Cancer Detect Prev. 1988;12(1-6):597-604.

PMID:
3052841
37.

Hodgkin's disease-derived cell lines--conflicting clues for the origin of Hodgkin's disease?

Drexler HG, Amlot PL, Minowada J.

Leukemia. 1987 Sep;1(9):629-37. Review.

PMID:
3312848
38.

Oral allergy syndrome (OAS): symptoms of IgE-mediated hypersensitivity to foods.

Amlot PL, Kemeny DM, Zachary C, Parkes P, Lessof MH.

Clin Allergy. 1987 Jan;17(1):33-42.

PMID:
3829369
39.

Sub-class of IgG in allergic disease. I. IgG sub-class antibodies in immediate and non-immediate food allergy.

Kemeny DM, Urbanek R, Amlot PL, Ciclitira PJ, Richards D, Lessof MH.

Clin Allergy. 1986 Nov;16(6):571-81.

PMID:
3791631
40.
42.
44.

Splenic dependence of the antibody response to thymus-independent (TI-2) antigens.

Amlot PL, Grennan D, Humphrey JH.

Eur J Immunol. 1985 May;15(5):508-12.

PMID:
2581791
45.
46.

Type I allergy to egg and milk proteins: comparison of skin prick tests with nasal, buccal and gastric provocation tests.

Amlot PL, Urbanek R, Youlten LJ, Kemeny M, Lessof MH.

Int Arch Allergy Appl Immunol. 1985;77(1-2):171-3.

PMID:
4008071
47.

Lymphoproliferative malignancy in rheumatoid arthritis: a study of 20 cases.

Symmons DP, Ahern M, Bacon PA, Hawkins CF, Amlot PL, Jones EL, Prior P, Scott DL.

Ann Rheum Dis. 1984 Apr;43(2):132-5.

48.

Atopy--a favourable prognostic factor for survival in Hodgkin's disease.

Amlot PL, Slaney J, Brown R.

Br J Cancer. 1983 Aug;48(2):209-15.

49.

Immune complexes in Hodgkin's disease: isolation, immunochemical and physico-chemical analysis.

Kilgallon W, Amlot PL, Williams BD.

Clin Exp Immunol. 1983 Aug;53(2):308-18.

50.

Collagen production by human mesothelial cells in vitro.

Harvey W, Amlot PL.

J Pathol. 1983 Mar;139(3):337-47.

PMID:
6834177

Supplemental Content

Loading ...
Support Center